{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:20:47Z","timestamp":1791534047982,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1746-1596-9-72","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T16:02:50Z","timestamp":1395763370000},"source":"Crossref","is-referenced-by-count":16,"title":["Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Ola H","family":"Nada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa S","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda H","family":"Abou Gabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"issue":"4","key":"952_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.9-4-422","volume":"9","author":"N Marina","year":"2004","unstructured":"Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for Pediatric osteosarcoma. Oncologist. 2004, 9 (4): 422-441. 10.1634\/theoncologist.9-4-422.","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"952_CR2","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1038\/bmt.2008.71","volume":"41","author":"F Fagioli","year":"2008","unstructured":"Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant. 2008, 41 (Suppl 2): S131-S134.","journal-title":"Bone Marrow Transplant"},{"key":"952_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BLO.0b013e31802b683c","volume":"454","author":"RC Haydon","year":"2007","unstructured":"Haydon RC, Luu HH, He TC: Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2007, 454: 237-246.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"952_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/dna.2006.0505","volume":"26","author":"M Kansara","year":"2007","unstructured":"Kansara M, Thomas DM: Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007, 26 (1): 1-18. 10.1089\/dna.2006.0505.","journal-title":"DNA Cell Biol"},{"issue":"7","key":"952_CR5","doi-asserted-by":"crossref","first-page":"vii: 320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS: Osteosarcoma. Ann Oncol. 2010, 21 (7): vii: 320-vii: 325.","journal-title":"Ann Oncol"},{"issue":"3","key":"952_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/157488708785700267","volume":"3","author":"A Sakamoto","year":"2008","unstructured":"Sakamoto A, Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials. 2008, 3 (3): 228-231. 10.2174\/157488708785700267.","journal-title":"Rev Recent Clin Trials"},{"issue":"2","key":"952_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1586\/14737140.7.2.169","volume":"7","author":"F Lamoureux","year":"2007","unstructured":"Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F: Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007, 7 (2): 169-181. 10.1586\/14737140.7.2.169.","journal-title":"Expert Rev Anticancer Ther"},{"key":"952_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1309\/UC6KQHLD9LV2KENN","volume":"125","author":"MJ Klein","year":"2006","unstructured":"Klein MJ, Siegal GP: Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006, 125: 555-581. 10.1309\/UC6KQHLD9LV2KENN.","journal-title":"Am J Clin Pathol"},{"key":"952_CR9","volume-title":"Pathology and Genetics of Tumors of Soft Tissue and Bone","author":"C Fletcher","year":"2013","unstructured":"Fletcher C, Unni K, Mertens F: Conventional Osteosarcoma. Pathology and Genetics of Tumors of Soft Tissue and Bone. 2013, Lyon, France: IARC Press, 4","edition":"4"},{"issue":"7","key":"952_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1586\/14737140.6.7.1075","volume":"6","author":"AJ Chou","year":"2006","unstructured":"Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006, 6 (7): 1075-1085. 10.1586\/14737140.6.7.1075.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"952_CR11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/cncr.21263","volume":"104","author":"V Mialou","year":"2005","unstructured":"Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles AS, Hartmann O: Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome\u2013the French pediatric experience. Cancer. 2005, 104 (5): 1100-1109. 10.1002\/cncr.21263.","journal-title":"Cancer"},{"issue":"6","key":"952_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ctrv.2006.05.005","volume":"32","author":"A Longhi","year":"2006","unstructured":"Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006, 32 (6): 423-436. 10.1016\/j.ctrv.2006.05.005.","journal-title":"Cancer Treat Rev"},{"key":"952_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-1172-2-6","volume":"2","author":"P Picci","year":"2007","unstructured":"Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007, 2: 6-10.1186\/1750-1172-2-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"9082","key":"952_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","volume":"350","author":"RL Souhami","year":"1997","unstructured":"Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D: Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997, 350 (9082): 911-917. 10.1016\/S0140-6736(97)02307-6.","journal-title":"Lancet"},{"issue":"15","key":"952_CR15","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1200\/JCO.2006.07.7776","volume":"25","author":"CL Schwartz","year":"2007","unstructured":"Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P: Children\u2019s Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children\u2019s Oncology Group. J Clin Oncol. 2007, 25 (15): 2057-2062. 10.1200\/JCO.2006.07.7776.","journal-title":"J Clin Oncol"},{"issue":"2","key":"952_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4161\/cbt.8.2.7385","volume":"8","author":"ML Tan","year":"2009","unstructured":"Tan ML, Choong PF, Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther. 2009, 8 (2): 106-117. 10.4161\/cbt.8.2.7385.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"952_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","volume":"23","author":"B Kempf-Bielack","year":"2005","unstructured":"Kempf-Bielack B, Bielack SS, J\u00fcrgens H, Branscheid D, Berdel WE, Exner GU, G\u00f6bel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005, 23 (3): 559-568.","journal-title":"J Clin Oncol"},{"key":"952_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00003086-200204000-00008","volume":"397","author":"B Carsi","year":"2002","unstructured":"Carsi B, Rock MG: Primary osteosarcoma in adults older than 40\u00a0years. Clin Orthop Relat Res. 2002, 397: 53-61.","journal-title":"Clin Orthop Relat Res"},{"key":"952_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.blo.0000093898.12372.6c","volume":"415","author":"RK Heck Jr","year":"2003","unstructured":"Heck RK, Stacy GS, Flaherty MJ, Montag AG, Peabody TD, Simon MA: A comparison study of staging systems for bone sarcomas. Clin Orthop Relat Res. 2003, 415: 64-71.","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"952_CR20","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/cncr.21724","volume":"106","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006, 106 (5): 1154-1161. 10.1002\/cncr.21724.","journal-title":"Cancer"},{"issue":"3","key":"952_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, J\u00fcrgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002, 20 (3): 776-790. 10.1200\/JCO.20.3.776.","journal-title":"J Clin Oncol"},{"issue":"3","key":"952_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1302\/0301-620X.84B3.12019","volume":"84","author":"RJ Grimer","year":"2002","unstructured":"Grimer RJ, Taminiau AM, Cannon SR: Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg (Br). 2002, 84 (3): 395-400. 10.1302\/0301-620X.84B3.12019.","journal-title":"J Bone Joint Surg (Br)"},{"issue":"1","key":"952_CR23","first-page":"171","volume":"9","author":"G Bacci","year":"2002","unstructured":"Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M: Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002, 9 (1): 171-175.","journal-title":"Oncol Rep"},{"issue":"5","key":"952_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/annonc\/mdn723","volume":"20","author":"MS Kim","year":"2009","unstructured":"Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009, 20 (5): 955-960. 10.1093\/annonc\/mdn723.","journal-title":"Ann Oncol"},{"issue":"4","key":"952_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/carcin\/bgp330","volume":"31","author":"C Yang","year":"2010","unstructured":"Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z: The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis. 2010, 31 (4): 552-558. 10.1093\/carcin\/bgp330.","journal-title":"Carcinogenesis"},{"issue":"9","key":"952_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1349-7006.2007.00558.x","volume":"98","author":"E Kikuchi","year":"2007","unstructured":"Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M: HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007, 98 (9): 1424-1430. 10.1111\/j.1349-7006.2007.00558.x.","journal-title":"Cancer Sci"},{"issue":"12","key":"952_CR27","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/j.1349-7006.2009.01329.x","volume":"100","author":"I Homma","year":"2009","unstructured":"Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Sato N, Tsukamoto T: Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci. 2009, 100 (12): 2331-2334. 10.1111\/j.1349-7006.2009.01329.x.","journal-title":"Cancer Sci"},{"issue":"2","key":"952_CR28","first-page":"487","volume":"25","author":"J Buben\u00edk","year":"2004","unstructured":"Buben\u00edk J: MHC class I down-regulation: tumor escape from immune surveillance? (Review). Int J Oncol. 2004, 25 (2): 487-491.","journal-title":"Int J Oncol"},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/(SICI)1097-0215(19971219)74:6<582::AID-IJC4>3.0.CO;2-Q","volume":"74","author":"SB Hosch","year":"1997","unstructured":"Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K: Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer. 1997, 74: 582-587. 10.1002\/(SICI)1097-0215(19971219)74:6<582::AID-IJC4>3.0.CO;2-Q.","journal-title":"Int J Cancer"},{"issue":"3","key":"952_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0002-9440(10)65321-7","volume":"154","author":"T Kageshita","year":"1999","unstructured":"Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999, 154 (3): 745-754. 10.1016\/S0002-9440(10)65321-7.","journal-title":"Am J Pathol"},{"issue":"1","key":"952_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.67.11.1","volume":"11","author":"M Vitale","year":"2005","unstructured":"Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S: HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005, 11 (1): 67-72.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"952_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.21303","volume":"118","author":"NF Watson","year":"2006","unstructured":"Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006, 118 (1): 6-10. 10.1002\/ijc.21303.","journal-title":"Int J Cancer"},{"issue":"4","key":"952_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.juro.2006.11.082","volume":"177","author":"H Kitamura","year":"2007","unstructured":"Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T: Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007, 177 (4): 1269-1272. 10.1016\/j.juro.2006.11.082.","journal-title":"J Urol"},{"issue":"9","key":"952_CR34","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/sj.bjc.6604715","volume":"99","author":"Y Mizukami","year":"2008","unstructured":"Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H: Downregulation of HLA Class I molecules in the tumor is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2008, 99 (9): 1462-1467. 10.1038\/sj.bjc.6604715.","journal-title":"Br J Cancer"},{"key":"952_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/1471-2407-11-454","volume":"11","author":"K Kaneko","year":"2011","unstructured":"Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S: Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 2011, 11: 454-10.1186\/1471-2407-11-454.","journal-title":"BMC Cancer"},{"issue":"9","key":"952_CR36","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1158\/0008-5472.CAN-04-4621","volume":"65","author":"SE Al-Batran","year":"2005","unstructured":"Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, J\u00e4ger E: Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 2005, 65 (9): 3937-3941. 10.1158\/0008-5472.CAN-04-4621.","journal-title":"Cancer Res"},{"issue":"1","key":"952_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO;2-4","volume":"95","author":"J Kamarashev","year":"2001","unstructured":"Kamarashev J, Ferrone S, Seifert B, B\u00f6ni R, Nestle FO, Burg G, Dummer R: TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer. 2001, 95 (1): 23-28. 10.1002\/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO;2-4.","journal-title":"Int J Cancer"},{"issue":"2","key":"952_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ijc.21163","volume":"117","author":"Z Madjd","year":"2005","unstructured":"Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005, 117 (2): 248-255. 10.1002\/ijc.21163.","journal-title":"Int J Cancer"},{"issue":"11","key":"952_CR39","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00262-008-0515-4","volume":"57","author":"B Seliger","year":"2008","unstructured":"Seliger B: Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008, 57 (11): 1719-1726. 10.1007\/s00262-008-0515-4.","journal-title":"Cancer Immunol Immunother"},{"key":"952_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","volume":"18","author":"F Garrido","year":"1997","unstructured":"Garrido F, Ruiz-Cabello F, Cabrera T, P\u00e9rez-Villar JJ, L\u00f3pez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today. 1997, 18: 89-95. 10.1016\/S0167-5699(96)10075-X.","journal-title":"Immunol Today"},{"issue":"5","key":"952_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1440-1827.2012.02789.x","volume":"62","author":"T Torigoe","year":"2012","unstructured":"Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T, Sato N: Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 2012, 62 (5): 303-308. 10.1111\/j.1440-1827.2012.02789.x.","journal-title":"Pathol Int"},{"issue":"4","key":"952_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1440-1827.2009.02353.x","volume":"59","author":"N Sato","year":"2009","unstructured":"Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T: Molecular pathological approaches to human tumor immunology. Pathol Int. 2009, 59 (4): 205-217. 10.1111\/j.1440-1827.2009.02353.x.","journal-title":"Pathol Int"},{"issue":"7","key":"952_CR43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/jso.21029","volume":"97","author":"S Ishigami","year":"2008","unstructured":"Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol. 2008, 97 (7): 605-608. 10.1002\/jso.21029.","journal-title":"J Surg Oncol"},{"issue":"12","key":"952_CR44","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","volume":"97","author":"T Tsukahara","year":"2006","unstructured":"Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N: Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006, 97 (12): 1374-1380. 10.1111\/j.1349-7006.2006.00317.x.","journal-title":"Cancer Sci"},{"issue":"1","key":"952_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1746-1596-8-183","volume":"8","author":"H Zhu","year":"2013","unstructured":"Zhu H, Tang J, Tang M, Cai H: Up regulation of SOX9 in osteosarcoma and its association with tumor progression and patients\u2019 prognosis. Diagn Pathol. 2013, 8 (1): 183-10.1186\/1746-1596-8-183.","journal-title":"Diagn Pathol"},{"key":"952_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1746-1596-7-84","volume":"7","author":"X Liang","year":"2012","unstructured":"Liang X, Wang D, Wang Y, Zhou Z, Zhang J, Li J: Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol. 2012, 7: 84-10.1186\/1746-1596-7-84.","journal-title":"Diagn Pathol"},{"issue":"6","key":"952_CR47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.1984.2.6.617","volume":"2","author":"K Winkler","year":"1984","unstructured":"Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, G\u00f6bel U: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German\/Austrian study. J Clin Oncol. 1984, 2 (6): 617-624.","journal-title":"J Clin Oncol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-9-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:55:04Z","timestamp":1689083704000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-9-72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-9-72","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,25]]},"article-number":"72"}}